Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Cardiomyopathy

Topoisomerase IIb (TOP2B)

Mouse studies suggest TOP2B expression could help predict the risk of doxorubicin-induced cardiomyopathy. Cardiomyocytes from doxorubicin-treated mice with cardiac-specific Top2b deficiency showed lower DNA damage responses and apoptosis and greater mitochondrial biosynthesis and function than cardiomyocytes with normal Top2b expression. In mice with cardiac-specific Top2b deficiency, doxorubicin induced no change in left ventricular ejection fraction, a clinical measure of cardiomyopathy, whereas the drug decreased ejection fractions in wild-type controls. Ongoing work includes determining whether TOP2B expression correlates with cardiomyopathy in patients treated with doxorubicin.

SciBX 5(43); doi:10.1038/scibx.2012.1139
Published online Nov. 1, 2012

Patented by The University of Texas MD Anderson Cancer Center; available for licensing
Contact: Natalie Wright, The University of Texas MD Anderson Cancer Center, Houston, Texas
e-mail:
nwright@mdanderson.org

Zhang, S. et al. Nat. Med.; published online Oct. 28, 2012;
doi:10.1038/nm.2919
Contact: Edward T.H. Yeh, The University of Texas MD Anderson Cancer Center, Houston, Texas
e-mail:
etyeh@mdanderson.org